Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial

The authors report on a randomized, multicenter, open-label, clinical trial involving 500 patients with 1460 saphenous vein grafts (SVG) who were assigned to three groups: (1) ticagrelor + asprin (ASA), (2) ticagrelor alone, or (3) ASA alone.  Neither patients nor physicians were blinded to the allocation.  The primary outcome was SVG patency at one year, assessed by either coronary angiography or CT angiography.
Results: The SVG patency rates for groups 1,2, and 3 were 88.7%, 82.8%, and 76.5%.  The differences between group 1 and group 3 were significant at p